Page last updated: 2024-08-21

isoxazoles and Depression, Involutional

isoxazoles has been researched along with Depression, Involutional in 8 studies

Research

Studies (8)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (12.50)	29.6817
2010's	5 (62.50)	24.3611
2020's	2 (25.00)	2.80

Authors

Authors	Studies
Boileau, I; Gill, T; Houle, S; Hutchison, MG; Jetly, R; Kish, SJ; McCluskey, T; Meyer, JH; Rhind, SG; Richardson, JD; Tong, J; Vasdev, N; Warsh, J; Watling, SE	1
Asgharnejad, M; Buhl, D; Dijkstra, F; Jacobs, G; Klaassen, E; O'Donnell, P; Rosen, L; van Gerven, J; Zuiker, R	1
Alzarea, S; Rahman, S	1
Conway, C; Cristancho, P; Jewkes, D; Mon, T	1
Preskorn, SH	1
Bäuml, J; Förstl, H; Gebhart, C; Hüther, R; Mirisch, S	1
Liang, CS; Yang, FW	1
Ebert, B; Kasper, S; Larsen, K; Tonnoir, B	1

Trials

2 trial(s) available for isoxazoles and Depression, Involutional

Article	Year
Central nervous system effects of TAK-653, an investigational alpha-amino-3-hydroxy-5-methyl-4-isoxazole receptor (AMPAR) positive allosteric modulator in healthy volunteers. Translational psychiatry, 2022, 09-24, Volume: 12, Issue:1 Topics: Central Nervous System; Depressive Disorder, Major; Double-Blind Method; Healthy Volunteers; Humans; Isoxazoles; Receptors, AMPA	2022
Combining escitalopram with gaboxadol provides no additional benefit in the treatment of patients with severe major depressive disorder. The international journal of neuropsychopharmacology, 2012, Volume: 15, Issue:6 Topics: Adolescent; Adult; Aged; Analgesics; Analysis of Variance; Antidepressive Agents, Second-Generation; Citalopram; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; International Cooperation; Isoxazoles; Male; Middle Aged; Psychiatric Status Rating Scales; Treatment Outcome; Young Adult	2012

Article

Year

Central nervous system effects of TAK-653, an investigational alpha-amino-3-hydroxy-5-methyl-4-isoxazole receptor (AMPAR) positive allosteric modulator in healthy volunteers.

Translational psychiatry, 2022, 09-24, Volume: 12, Issue:1

Topics: Central Nervous System; Depressive Disorder, Major; Double-Blind Method; Healthy Volunteers; Humans; Isoxazoles; Receptors, AMPA

2022

Combining escitalopram with gaboxadol provides no additional benefit in the treatment of patients with severe major depressive disorder.

The international journal of neuropsychopharmacology, 2012, Volume: 15, Issue:6

Topics: Adolescent; Adult; Aged; Analgesics; Analysis of Variance; Antidepressive Agents, Second-Generation; Citalopram; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; International Cooperation; Isoxazoles; Male; Middle Aged; Psychiatric Status Rating Scales; Treatment Outcome; Young Adult

2012

Other Studies

6 other study(ies) available for isoxazoles and Depression, Involutional

Article	Year
Imaging of astrocytes in posttraumatic stress disorder: A PET study with the monoamine oxidase B radioligand [ European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2022, Volume: 54 Topics: Astrocytes; Brain; Depressive Disorder, Major; Humans; Isoxazoles; Monoamine Oxidase; Oxazolidinones; Positron-Emission Tomography; Stress Disorders, Post-Traumatic	2022
Alpha-7 nicotinic receptor allosteric modulator PNU120596 prevents lipopolysaccharide-induced anxiety, cognitive deficit and depression-like behaviors in mice. Behavioural brain research, 2019, 07-02, Volume: 366 Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Antidepressive Agents; Anxiety; Anxiety Disorders; Astrocytes; Cognition; Cognition Disorders; Cognitive Dysfunction; Cytokines; Depression; Depressive Disorder, Major; Disease Models, Animal; Hippocampus; Inflammation; Isoxazoles; Lipopolysaccharides; Male; Mice; Mice, Inbred C57BL; Microglia; Phenylurea Compounds; Prefrontal Cortex	2019
Successful use of right unilateral ECT for catatonia: a case series. The journal of ECT, 2014, Volume: 30, Issue:1 Topics: Adolescent; Adult; Aged, 80 and over; Antipsychotic Agents; Bipolar Disorder; Catatonia; Depressive Disorder, Major; Electroconvulsive Therapy; Female; GABA Modulators; Humans; Isoxazoles; Lorazepam; Lupus Erythematosus, Systemic; Male; Paliperidone Palmitate; Psychotic Disorders; Pyrimidines; Schizophrenia, Catatonic; Seizures; Treatment Outcome; Young Adult	2014
Complexities of personalized medicine: how genes, drug-drug interactions, dosing schedules, and other factors can combine to produce clinically meaningful differences in a drug's effect. Journal of psychiatric practice, 2013, Volume: 19, Issue:5 Topics: Affective Disorders, Psychotic; Aged; Antipsychotic Agents; Depressive Disorder, Major; Dizziness; Drug Interactions; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Isoxazoles; Male; Paroxetine; Pharmacogenetics; Piperidines; Precision Medicine	2013
Choreatic symptoms during and after treatment with paliperidone and escitalopram. Pharmacopsychiatry, 2008, Volume: 41, Issue:5 Topics: Antidepressive Agents, Second-Generation; Antipsychotic Agents; Chorea; Citalopram; Depressive Disorder, Major; Female; Humans; Isoxazoles; Middle Aged; Paliperidone Palmitate; Psychotic Disorders; Pyrimidines	2008
Paliperidone augmentation for treatment-resistant depression: a case report. Journal of clinical psychopharmacology, 2011, Volume: 31, Issue:2 Topics: Cyclohexanols; Depressive Disorder, Major; Drug Resistance; Drug Therapy, Combination; Female; Humans; Isoxazoles; Middle Aged; Paliperidone Palmitate; Pyrimidines; Treatment Outcome; Venlafaxine Hydrochloride	2011